Patient FAQs

Book Now

How Can MacuMira Improve My Vision & Other Frequently Asked Questions

MacuMira delivers gentle microcurrent energy through your eyelids that stimulates the retina. This is designed to help support your visual function and slow the progression of dry AMD.

Treatments take place at your MacuMira provider’s eye care office, with each session lasting about 32 minutes.

During the treatment, you will be seated or reclined while a headset is placed over your eyes.
Contoured eye cups rest gently on your closed eyelids, delivering microcurrent stimulation to the retina. Many patients find it relaxing enough to fall asleep during treatment.

Some patients experience a mild tingling sensation or brief patterns of light during the session. These are known as phosphenes and are a normal response to the stimulation.

After the session, you can continue with your day as normal with no downtime or restrictions.

No, MacuMira treatment isn’t painful, and there are no needles or drugs involved. It’s completely noninvasive.

Some patients feel a slight tingling sensation during the session, but it’s generally very comfortable and well-tolerated.

Most patients report vision improvements within the first 10 days of treatment.

Results vary, but many dry AMD patients describe better contrast (ability to see detail in dim light), sharper reading vision, or less glare sensitivity after the initial 10-day phase of treatment.

Unfortunately, there is currently no cure for dry AMD. MacuMira is not a cure. However, it may help improve functional vision and slow progressive vision loss in people with dry AMD.

Many patients who receive MacuMira begin to notice improvements within the first 10 days during the initial loading phase of treatment.

To maintain those gains, follow-up treatments are typically recommended at least every 3 months. Your optometrist or ophthalmologist will determine the ideal schedule based on your condition and how your vision responds.

Yes, MacuMira can be used alongside your current vision aids and AREDS or AREDS2 supplements. It doesn’t interfere with any other aspects of your eye care.

Yes! MacuMira is a noninvasive treatment that has demonstrated a clinically proven strong safety profile. It has undergone rigorous safety review and licensing by Health Canada and meets the standards required of Class II medical devices.

The stimulation uses microcurrent levels that are incapable of causing muscle contraction and remain well below thresholds associated with discomfort or tissue damage.

No adverse events were reported in the prospective clinical study, and the treatment has now been used in clinical settings with excellent tolerability across thousands of treatment sessions.

Patients typically find the treatment comfortable and easy to complete. It doesn’t involve pills, lasers, injections, or any surgery.

There are currently no other authorized treatments for dry AMD, and nothing else has been shown to improve vision lost to dry AMD.

After diagnosing early stage dry AMD, eye care providers typically recommend lifestyle changes such as healthy eating, quitting smoking, and regular exercise to potentially slow the progression of dry AMD.

For intermediate dry AMD, eye care providers typically recommend dietary supplements, such as AREDS or AREDS2 vitamins. These may slow the progression of the disease, but do not improve vision.

Articles

Understanding how dry AMD affects you or your family member can make it a little easier to navigate. Learn more about this eye disease in our articles.

Your Guide to Dry Age-related Macular Degeneration: Key Treatments and Care Strategies

Blog

Dry age-related macular degeneration (AMD) is a progressive eye condition that affects the macula, leading to gradual central vision loss. As the most common form of AMD, it typically develops slowly. Early detection and management are crucial for maintaining eye health. Understanding  In dry AMD, the macula thins over time, often accompanied by the formation of […]

Read More… from Your Guide to Dry Age-related Macular Degeneration: Key Treatments and Care Strategies

July 23, 2025
MacuMira

Can Wet Macular Degeneration Turn Into Dry Macular Degeneration?

Blog

Age-related macular degeneration (AMD) is one of the leading causes of vision loss in older adults. It comes in two forms: dry (atrophic) and wet (neovascular). While dry AMD progresses gradually over time, wet AMD can cause sudden and severe vision loss. A common question among patients and caregivers is whether wet macular degeneration can turn […]

Read More… from Can Wet Macular Degeneration Turn Into Dry Macular Degeneration?

July 23, 2025
MacuMira

What is geographic atrophy (GA)?

Blog

How it’s related to dry AMD and who’s the most at risk For those with dry age-related macular degeneration (dry AMD), there’s always a risk that this condition could develop into geographic atrophy (GA), a condition where retinal pigment epithelial (RPE) cells start to die off. Research estimates that there are approximately 180,000 new cases of GA […]

Read More… from What is geographic atrophy (GA)?

July 23, 2025
MacuMira

Dry age-related macular degeneration (AMD) is a progressive eye condition that affects the macula, leading to gradual central vision loss. As the most common form of AMD, it typically develops slowly. Early detection and management are crucial for maintaining eye health. Understanding  In dry AMD, the macula thins over time, often accompanied by the formation of […]

Read More… from Your Guide to Dry Age-related Macular Degeneration: Key Treatments and Care Strategies

Age-related macular degeneration (AMD) is one of the leading causes of vision loss in older adults. It comes in two forms: dry (atrophic) and wet (neovascular). While dry AMD progresses gradually over time, wet AMD can cause sudden and severe vision loss. A common question among patients and caregivers is whether wet macular degeneration can turn […]

Read More… from Can Wet Macular Degeneration Turn Into Dry Macular Degeneration?

How it’s related to dry AMD and who’s the most at risk For those with dry age-related macular degeneration (dry AMD), there’s always a risk that this condition could develop into geographic atrophy (GA), a condition where retinal pigment epithelial (RPE) cells start to die off. Research estimates that there are approximately 180,000 new cases of GA […]

Read More… from What is geographic atrophy (GA)?

instagram facebook facebook2 pinterest twitter google-plus google linkedin2 yelp youtube phone location calendar share2 link star-full star star-half chevron-right chevron-left chevron-down chevron-up envelope fax